Briakinumab
Based on 1 Customer Validation
Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : ≥99.0%
- CAS. Nr.: 339308-60-0
- Molecular Weight:143.86 kDa
-
Speicherung:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-P9909
Ustekinumab -
HY-108852
BasiliximabAnti-IL-2R mAb -
HY-P9945
MepolizumabIL-5 Inhibitor -
HY-P99256
TildrakizumabAnti-IL-23 mAb -
HY-P9907
TrastuzumabHER2 Blocking Antibody -
HY-P9908
AdalimumabTNF-α Inhibitor -
HY-P9956
SiltuximabAnti-IL-6 mAb -
HY-P9925
BrodalumabAnti-IL-17R mAb -
HY-P99737
MirikizumabIL-23 Antibody -
HY-P99112
SatralizumabIL-6R Inhibitor -
HY-P990876
Afimkibart (WT IgG1)Trimeric TL1A Antibody -
HY-P9926
DupilumabIL-4Rα Inhibitor
Biologische Aktivität
Beschreibung
Isotype
Human IgG1 lambda2
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
[1]|
IL-12 |
IL-23 |
In Vitro
Briakinumab targets the p40 molecule shared by interleukin-12 and interleukin-23[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 lambda
Anwendung
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized IL-12 beta Protein, Human (HEK293, HY-P70617) can bind Briakinumab. The EC50 for this effect is 10.66 ng/mL.
Chemical Information
-
CAS. Nr. 339308-60-0
-
Appearance Liquid
-
Molecular Weight 143.86 kDa
-
Color Colorless to light yellow
-
SMILES
[Briakinumab]
-
Synonyms
ABT-874
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
-
Data Sheet (256 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
[1]. Panaccione R, et, al. Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflamm Bowel Dis. 2015 Jun;21(6):1329-40. [Content Brief]
[2]. Reich K, et, al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med. 2011 Oct 27;365(17):1586-96. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Briakinumab Related Classifications
HY-P99486 Related Classifications
Powered by Bioz